

ASX ANNOUNCEMENT MARKET RELEASE

7 November 2022

ARTRYA GAINS UK REGULATORY APPROVAL

Perth, Western Australia., (7 November 2022): Australian medical technology company, Artrya Limited (ASX: AYA, Artrya or the Company) has received regulatory approval for its Salix Coronary Anatomy (SCA) product in the United Kingdom.

The European Notified Body (BSI) has notified Artrya that the assessment for UKCA Class 2 Certification has been completed and they will recommend certification of the Salix V2.0 Software for marketing into the United Kingdom.

The BSI assessment scope includes UKCA certification in accordance with the UK Medical Devices Regulations 2002 and Artrya's Salix AI Coronary Software met or exceeded all regulatory requirements.

Once the UKCA certificate has been issued by BSI, Artrya is able to market the Salix software in the UK.

Artrya Managing Director and CEO John Barrington AM said UK regulatory approval was a landmark moment for the company.

"Our business activities in the UK are advanced and Artrya is well positioned to take advantage of the regulatory approval in this significant market," he said.

Artrya already has a four-year contract in place to supply 1,250 National Health Service Trust Hospitals throughout the UK with the SCA product. The company is now able to approach these hospitals to finalise arrangements for the product roll out.

"This is Artrya's biggest market opportunity to date and we aim to take full advantage of it," Mr Barrington said.

Other business development activities in the UK are well advanced for use of the SCA product within clinical practices outside of the National Health Service network.

This announcement was approved by the Artrya Managing Director and CEO.

For further information please contact:

Investor Enquiries:

John Barrington
Artrya Limited
+61 419 850 502
investors@artrya.com

Media Enquiries:

Brett McCarthy
Artrya Limited
+61 401 704 451
brett.mccarthy@artrya.com

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA).

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

For more information, see www.artrya.com